Emerging data suggest that hypercholesterolemia has stimulatory effects on adaptive immunity and that these effects can promote atherosclerosis and perhaps other inflammatory diseases. However, research in this area has relied primarily on inbred strains of mice whose adaptive immune system can differ substantially from that of humans. Moreover, the genetically induced hypercholesterolemia in these models typically results in plasma cholesterol levels that are much higher than those in most humans. To overcome these obstacles, we studied human immune system–reconstituted mice (hu-mice) rendered hypercholesterolemic by treatment with adeno-associated virus 8–proprotein convertase subtilisin/kexin type 9 (AAV8-PCSK9) and a high-fat/high-cholesterol Western-type diet (WD). These mice had a high percentage of human T cells and moderate hypercholesterolemia. Compared with hu-mice that had lower plasma cholesterol, the PCSK9-WD mice developed a T cell–mediated inflammatory response in the lung and liver. Human CD4+ and CD8+ T cells bearing an effector memory phenotype were significantly elevated in the blood, spleen, and lungs of PCSK9-WD hu-mice, whereas splenic and circulating regulatory T cells were reduced. These data show that moderately high plasma cholesterol can disrupt human T cell homeostasis in vivo. This process may not only exacerbate atherosclerosis, but also contribute to T cell–mediated inflammatory diseases in the hypercholesterolemia setting.

Find the latest version:
http://jci.me/97785-pdf
Hypercholesterolemia induces T cell expansion in humanized immune mice

Jonathan D. Proto,1 Amanda C. Doran,1 Manikandan Subramanian,1 Hui Wang,2,3 Mingyou Zhang,2 Erdi Sozen,1,4 Christina C. Rymond,1 George Kurialose,1 Vivette D’Agati,1 Robert Winchester,1 Megan Sykes,1,2,6 Yong-Guang Yang,1,3,7 and Ira Tabas1,7

1Department of Medicine, 2Columbia Center for Translational Immunology, and 3Humanized Mouse Core, Columbia University Medical Center, New York, New York, USA. 4Department of Biochemistry, Faculty of Medicine, Genetic and Metabolic Diseases Research and Investigation Center (GEHAM), Marmara University, Istanbul, Turkey. 5Department of Pathology and Cell Biology, 6Department of Microbiology & Immunology and Department of Surgery, and 7Department of Physiology and Cellular Biophysics, Columbia University Medical Center, New York, New York, USA.

Emerging data suggest that hypercholesterolemia has stimulatory effects on adaptive immunity and that these effects can promote atherosclerosis and perhaps other inflammatory diseases. However, research in this area has relied primarily on inbred strains of mice whose adaptive immune system can differ substantially from that of humans. Moreover, the genetically induced hypercholesterolemia in these models typically results in plasma cholesterol levels that are much higher than those in most humans. To overcome these obstacles, we studied human immune system–reconstituted mice (hu-mice) rendered hypercholesterolemic by treatment with adeno-associated virus 8–proprotein convertase subtilisin/kexin type 9 (AAV8-PCSK9) and a high-fat/high-cholesterol Western-type diet (WD). These mice had a high percentage of human T cells and moderate hypercholesterolemia. Compared with hu-mice that had lower plasma cholesterol, the PCSK9-WD mice developed a T cell–mediated inflammatory response in the lung and liver. Human CD4+ and CD8+ T cells bearing an effector memory phenotype were significantly elevated in the blood, spleen, and lungs of PCSK9-WD hu-mice, whereas splenic and circulating regulatory T cells were reduced. These data show that moderately high plasma cholesterol can disrupt human T cell homeostasis in vivo. This process may not only exacerbate atherosclerosis, but also contribute to T cell–mediated inflammatory diseases in the hypercholesterolemia setting.

Introduction

Cardiovascular disease (CVD) remains the number one cause of death in the Western world. Dyslipidemia, the elevation of low-density lipoprotein cholesterol (LDL-C), is a critical risk factor for developing atherosclerosis, which is the underlying cause of CVD (1). In addition to traditional risk factors, accumulating evidence suggests that engagement of adaptive immunity also plays a causal role in CVD development. Increased circulating T effector memory (TEM) cells are present in patients with CVD and correlate with LDL-C levels (2). Indeed, several lines of evidence link T cell homeostasis to cholesterol metabolism (3–5). However, the majority of these studies have been carried out in mice. CVD researchers have adopted the inbred C57BL/6J mouse as the gold standard, and yet this mouse has strong T cell subset biases that are not reflected in the more complex human immune system (6, 7). One particular strain, the NOD-SCID gamma (NSG) mouse, lacks T cells, B cells, and natural killer cells and has defects in innate immunity (8). Following sublethal irradiation, NSG mice can be reconstituted with human fetal thymus grafts and fetal liver CD34+ hematopoietic stem cells, resulting in excellent reconstitution with human T cells and B cells (9, 10). Thus, we endeavored to use the NSG hu-mouse model to study the effect of elevated cholesterol on human T cells.

In order to induce hypercholesterolemia in hu-mice, we used a technique in which a gain-of-function mutant of proprotein convertase subtilisin/kexin type 9 (PCSK9), a negative regulator of hepatic LDL receptors (LDLRs), is expressed. PCSK9 decreases LDLR levels on hepatocytes, resulting in elevated plasma LDL-C (11). Combined with a high-cholesterol/high-fat Western-type diet (WD), expression of gain-of-function PCSK9 mutant by adeno-associated virus 8–mediated (AAV8-PCSK9) gene transduction results in elevated cholesterol. Because a single AAV8-gene injection results in lifelong expression of the gene in nondividing cells without an inflammatory response, this tool enabled us to study the effects of high cholesterol over several weeks. Interestingly, this method produced a level of plasma cholesterol in hu-mice that was much more closely aligned with that in hypercholesterol-emic humans, whereas most mouse models use genetic mutations to induce hypercholesterolemia (i.e., deletion of the LDL receptor or apolipoprotein E), which increases plasma cholesterol to...
much higher levels than observed in most humans. We report here that moderately high cholesterol in hu-mice was associated with increased TEM cells and decreased regulatory T cells, resulting in a T cell autoimmune phenotype, particularly in the lung and liver. Thus, hypercholesterolemia can activate an adaptive immune response in mice with human T cells. This process may contribute to atherosclerosis and other inflammatory diseases associated with hypercholesterolemia.

Results and Discussion
The first cohort of mice was injected with AAV8 carrying a gain-of-function PCSK9 gene and fed a WD (PCSK9-WD) approximately 8–9 weeks after transplantation of fetal liver CD34+ cells and thymus into NSG mice (hu-mice). Control hu-mice were injected with AAV8-GFP and fed normal mouse chow (GFP-chow). Both vectors were under the control of the thyroxine binding globulin (TBG) promoter, allowing for hepatocyte-specific expression (12). In comparison with most murine models of hypercholesterolemia, in which total plasma cholesterol levels rise above 1,000 mg/dl (13), PCSK9-WD mice demonstrated a plasma cholesterol value of approximately 300 mg/dl (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI97785DS1), which is much closer to the level seen in most humans with hypercholesterolemia (≥200 mg/dl). Of note, this value is lower than previously published values for WD-fed C57BL/6 mice treated with AAV8 gain-of-function PCSK9 (~850 mg/dl) (11). The lower value in our study appears to be related to irradiation, not genetic background, because WD-fed, non-irradiated NOD mice treated with AAV8 gain-of-function PCSK9 achieved a plasma cholesterol concentration of 715 ± 73 mg/dl. Unexpectedly, the PCSK9-WD mice became lethargic 10.5 weeks after AAV injection, corresponding to 19 weeks after transplant.

Although human CD4+ myeloid cell and human CD3+ T cell reconstitution did not differ among groups (Supplemental Figure 1, B and C), comparison of liver and lung tissue from PCSK9-WD mice with that from GFP-chow mice showed extensive mononuclear cell inflammation, and the livers showed evidence of fibrosis (Supplemental Figures 2 and 3). Immunostaining of lung tissue sections revealed that the infiltrating mononuclear cells were primarily human CD3+ T cells (Supplemental Figure 4).

For the second cohort of mice, we transduced hu-mice with either AAV8-TBG-eGFP or AAV8-TBG-PCSK9 combined with chow diet (GFP-chow, PCSK9-chow) or WD (GFP-WD, PCSK9-WD) at 12 weeks after transplant. At 3 weeks after viral trans-
CD8⁺ TEM cells were significantly increased in both the blood and the spleen. As with the previous experiment, PCSK9-WD livers had increased leukocyte infiltration and fibrosis, and in this case intermediate phenotypes were seen with the GFP-WD and PCSK9-chow cohorts (Figure 2, A–D). Immunohistochemical analysis of the livers revealed an approximately 5-fold increase in human CD3⁺ T cells in the livers of PCSK9-WD mice compared with GFP-chow mice (Figure 2, E and F). Similarly, histological analysis of lung tissue revealed perivascular and peribronchial inflammation (Figure 3, A and B). Flow analysis of lung human CD45⁺ cells showed an increased percentage of human T cells in the PCSK9-WD group (Figure 3C). In this cohort, we also examined the kidney for evidence of inflammation. H&E-stained sections were reviewed by a renal pathologist blinded to the groupings and scored for interstitial, perivascular, subcapsular, and peripelvic inflammation and for interstitial fibrosis.
percentage of inflammation was determined for each anatomic site, based on an estimated percentage of total cortical area and with inflammation in each cross-section examined (Supplemental Table 1 and Supplemental Figure 7). While not as striking as the findings in the liver and lung, there was an overall trend toward increased inflammation and fibrosis in the PCSK9-WD group compared with the other groups. Further, we analyzed pancreatic sections from GFP-chow and PCSK9-WD mice and found significant CD3⁺ T cell perivascular infiltrates in the latter group (Supplemental Figure 8). Given the relationship among hypercholesterolemia, TEM cells, and atherosclerosis, we asked whether any aortic lesion development occurred in these mice. At the time of sacrifice (12 weeks after transduction, 25 weeks after transplant), aortic roots were harvested and assessed for presence of atherosclerosis. No significant lesions were found in any groups (Supplemental Figure 9). This finding was not unexpected, as hypercholesterolemia was only moderate and NOD mice have previously been reported to be resistant to diet-induced hypercholesterolemia and atherosclerosis compared with C57BL/6 mice, which is the strain typically used for atherosclerosis studies (15).

In association with the increase in TEM cells, the proportion of human Tregs (CD4⁺ CD127low CD25⁺ Foxp3⁺) was decreased in the blood and spleen of PCSK9-WD mice (Figure 4). CCR5⁺ T cells, which have been implicated in autoimmune diseases such as rheumatoid arthritis and multiple sclerosis (16, 17), were elevated in both CD4⁺ and CD8⁺ subsets in the spleens of PCSK9-WD mice (Figure 4, B and C). However, anti–nuclear antibodies were not detected in any of the 4 cohorts (Supplemental Figure 10). Memory T cell population expansion has previously been characterized by increased CD4⁺ and CD8⁺ TEM cell subsets, decreased Tregs, and multiorgan pathology, including inflammation and fibrosis. Hypercholesterolemia-induced expansion of TEM cells is of particular interest given the association between TEM cells and atherosclerosis in animal models and in humans (2). While the most robust effect was observed in TEM cells in PCSK9-WD mice, there was also a mild, non–statistically significant expansion of splenic CD4⁺ TEM cells seen in hu-mice on Western diet alone (GFP-WD) or receiving AAV8-TBG-PCSK9 alone (PCSK9-chow). Concomitantly, we observed a modest increase in leukocytes in the livers of GFP-WD mice or PCSK9-chow mice, although these mice did not have increased liver fibrosis. This suggests that even modest elevations in plasma cholesterol may be able to stimulate the differentiation of TEM cells. While cholesterol would seem to be the common

Figure 3. Lung inflammation is increased in PCSK9-WD mice. (A and B) Lung sections were stained with H&E (scale bar, 200 μm) and scored for perivascular and peribronchial inflammation (n = 5–6 mice per group; *P < 0.05 vs. all other groups by 1-way ANOVA and Sidak’s post hoc analysis). (C) Analysis of human CD45⁺ and CD3⁺ cells by flow cytometry (n = 5–6 mice per group; *P < 0.05 vs. GFP-chow by Kruskal-Wallis test with Dunn’s multiple comparisons test).
factor driving these changes, we cannot rule out the contribution of other dietary elements such as saturated fat in the Western diet, which may have independent or additive effects to cholesterol itself.

In line with our findings, hyperlipidemia in mice has been reported to accelerate cardiac allograft rejection via a T cell-mediated process (23). Consistent with this report, we found increased CD4^+ and CD8^+ TEM cells in hypercholesterolemic Ldlr^{−/−} mice and AAV8-PCSK9–transduced WT mice after WD feeding. Future investigations will be necessary to determine the mechanism linking hypercholesterolemia to TEM cell expansion, but current evidence in the literature raises the possibility that enrichment of plasma membrane cholesterol in T cells may be involved. For example, increased membrane cholesterol has been reported to promote Th1 differentiation of CD4^+ T cells (24). Cholesterol in the plasma membrane has been shown to directly bind the TCR and mediate nanoclustering, which enhances the avidity of TCR interaction with antigen (4, 25). Interestingly, there are reports that T cells from patients with systemic lupus erythematosus (SLE) have elevated levels of cholesterol and disrupted localization of the raft-associated signaling molecule Lck (26, 27). Treatment of SLE T cells with a statin decreased cholesterol, normalized Lck localization, and reduced production of the cytokines IL-10 and IL-6 (26).

In contrast to murine models of hypercholesterolemia, in which values reach over 1,000 mg/dl, the use of humanized immune mice and AAV8-TBG-PCSK9 has allowed us to study the human immune system in the setting of cholesterol levels that are closer to those seen in hypercholesterolemic humans. Moderate hypercholesterolemia induces atherosclerosis in mice only after many months, and the mice in this study became ill with inflammatory liver and lung disease and eventually were sacrificed before lesions could develop. However, as demonstrated here, these mice can be used to study the pathophysiology of shorter-term disease and predisease processes in which dyslipidemia contributes to T cell autoimmunity. Moreover, future modifications of the model may make it possible to study longer term disease processes like atherosclerosis. In all cases, the use of humanized mice may provide a valuable model to conceive and validate therapeutic strategies prior to actual testing in humans.

Methods

For additional methods, please see supplemental material.

Mice. C57BL/6J (WT), B6.129S7-Ldlr^{−/−}/J (Ldlr^{−/−}), NOD.Cg-Pkrkdc^{−/−}Tg(II31)1YgyTg(CSF2)2YgyTg(KITLG)3Ygy (NOD.scid porcine IL-3-CSF2-KITLG), and NOD.Cg-Pkrkdc^{−/−}Tg(II31)Ygy^{−/−} (NOD.scid IL2rγnull mice abbreviated as NSG) mice were purchased from Jackson Laboratories (stock numbers 000664, 002207, 005557, and 004644, respectively) and housed in a specific pathogen–free microisolator environment. To generate humanized mice, NOD.scid porcine IL-3–CSF2-KITLG mice (cohort 1) or NSG mice (cohort 2) were conditioned with sublethal (1.0 Gy) total-body irradiation. Human fetal thymus fragments (1 mm^3) were implanted under the kidney capsule followed by intravenous injection with 2 × 10^5 autologous human fetal CD34^+ cells within 24 hours of fetal thymus transplantation. All recipients were injected intraperitoneally with anti–human CD2 monoclonal antibody (BTI 322; 400 μg/mouse) on days 0 and 7. Additional details are included in the supplemental methods.

Statistics. All results are mean ± SEM. Normality was determined using D’Agostino-Pearson and/or Shapiro-Wilk normality testing. P values for normally distributed data were calculated using either a 2-tailed Student’s t test or 1-way ANOVA with either Tukey’s or Sidak’s post hoc analysis. P values for non-normally distributed data were calculated using the Mann-Whitney rank sum test or the Kruskal-Wallis test with Dunn’s multiple comparisons testing. A P < 0.05 was considered significant. Pearson’s correlation coefficients (r) are represented by R^2 in Supplemental Table 2.
Study approval. All animal protocols were approved by the Columbia University IACUC.

Author contributions
JDP, RW, M Sykes, YGY, and IT conceived and designed the research. JDP, ACD, M Subramanian, HW, MZ, ES, CCR, GK, and YGY conducted experiments. VD conducted the pathological analysis of the kidneys from the hu-mice. All authors contributed to data analysis. JDP, ACD, and IT wrote the manuscript, and all authors contributed to manuscript editing.

Acknowledgments
This work was supported by NIH T32 training grant HL007343-28 (to JDP); an American Heart Association Fellow-to-Faculty award (to ACD); NIH grants DK106436 and AR064473 (to RW), AI064569 (to YGY), UC4DK104207, R01DK103585, and P01AI045897 (to M Sykes), and HL132412, HL075662, and HL127464 (to IT); and by an Interdisciplinary Research Initiative Seed (IRIS) Fund Program award from Columbia University Medical Center (to IT and M Sykes). These studies used flow cytometry facilities of the Columbia Center for Translational Immunology Flow Cytometry Core, the Columbia Diabetes and Endocrinology Research Center, and the Columbia Cancer Center, funded, respectively, through an NIH Shared Instrumentation Grant S10RR027050 and NIH Center Grants P50DK063608 and P30CA013696.

Address correspondence to: Ira Tabas, Department of Medicine, Columbia University Medical Center, 630 W 168th Street, New York, New York 10032, USA. Phone: 212.305.5669; Email: iat1@cumc.columbia.edu.

JDP’s present address is: Sanofi, Framingham, Massachusetts, USA.

M. Subramanian’s present address is: CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.